Related Experiment Video
Updated: Jul 7, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
[Anticoagulation in acute coronary syndrome. An update]
1Universitätsklinik Freiburg, Innere Medizin III (Kardiologie), Hugstetter Str. 55, 79106 Freiburg. martin.moser@uniklinik-freiburg.de
Abstract:
The acute coronary syndrome (ACS) is one of the most frequent diagnoses in cardiology. The therapeutic corner-stones of ACS are PCI (percutaneous coronary intervention) and inhibition of blood coagulation. Current antiplatelet therapy consists of aspirin in combination with clopidogrel and glycoprotein IIb/IIIa blockade if needed. Prasugel is a new antiplatelet agent that is in the process of being approved for routine clinical use. In terms of antithrombotic therapy latest developments focus on drugs with anti-factor Xa activity, such as fondaparinux, or direct anti-thrombin activity, such as bivalirudin. This review discusses latest developments in the field of anti-platelet and anti-thrombotic therapy for ACS.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Coronary Syndrome V: Nursing Management
